Therapy Directory

Tirzepatide clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Tirzepatide as a study intervention. Browse Tirzepatide recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 10:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

178

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Interventions: ALN-PNP, Tirzepatide, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 9
States / cities: Tucson, Arizona • Coronado, California • Pasadena, California + 6 more

Conditions: Endometrial Cancer, Endometrial Intraepithelial Neoplasia, Grade 1 Endometrial Endometrioid Carcinoma
Interventions: Tirzepatide; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Obesity, Methamphetamine Use Disorder
Interventions: Tirzepatide; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Chronic Weight Management
Interventions: ASC35 Injection B, for subcutaneous use, ASC35 Placebo Injection B, for subcutaneous use, Tirzepatide; Drug
Lead sponsor: Ascletis Pharma (China) Co., Limited; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Diabetes, Prostate Cancer
Interventions: Tirzepatide; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Obesity, Weight Gain
Interventions: Tirzepatide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 14
States / cities: Los Angeles, California • Sacramento, California • Wilmington, Delaware + 11 more

Conditions: Methamphetamine Use Disorder
Interventions: Tirzepatide, Placebo (saline); Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 228 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 4
States / cities: Los Angeles, California • San Francisco, California • Tulsa, Oklahoma + 1 more

Conditions: Diabetes Mellitus, Type 1, Overweight, Obesity
Interventions: Tirzepatide, Acetaminophen, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Central Centrifugal Cicatricial Alopecia (CCCA)
Interventions: Tirzepatide; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Baltimore, Maryland • Columbia, Maryland

Conditions: Obesity and Obesity-related Medical Conditions
Interventions: Mounjaro, Sleeve Gastrectomy; Drug · Procedure
Lead sponsor: Nicholas Skertich; Other
Eligibility: 18 Years to 65 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Psoriatic Arthritis, Overweight or Obesity
Interventions: Tirzepatide; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 53
States / cities: Avondale, Arizona • Chandler, Arizona • Flagstaff, Arizona + 48 more

Conditions: Diabetes Mellitus, Type 2
Interventions: NNC0519-0130, Placebo, Trizepatide; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 299 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 55
States / cities: Chula Vista, California • Fresno, California • Inglewood, California + 46 more

About this Tirzepatide clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Tirzepatide as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results: Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Tirzepatide.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Tirzepatide clinical trials

Filter and sort this therapy

Live official records

A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD

Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial Cancer

Tirzepatide for Obesity and Meth Use Disorder

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC35 Injection in Participants With Obesity or Overweight

Pre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot Feasibility Study

A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)

Randomized Controlled Trial of Tirzepatide for Methamphetamine Use Disorder

A Study of Tirzepatide (LY3298176) in Participants With Type 1 Diabetes Mellitus and Overweight or Obesity

Tirzepatide for Treatment of CCCA

Randomized Control Trial of Sleeve Gastrectomy With Tirzepatide in Maximizing Weight Loss

A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)

A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes

About this Tirzepatide clinical trials directory page